Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This phase II/III trial studies if contrast-enhanced ultrasound (CEUS) using a contrast
agent, perflutren lipid microspheres (Definity), can predict the early response of breast
cancer to neoadjuvant chemotherapy by estimating the pressure gradient between the breast
cancer and surrounding tissues. To estimate the pressures noninvasively, subharmonic (half of
fundamental frequency) aided pressure estimation (SHAPE) using CEUS will be utilized. The
study hypothesis is that the subharmonic signal difference in the tumor relative to the
normal tissue can predict breast cancer NAC response after 10% of therapy regimen.